+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
544759 GLPL

Goldline Pharmaceutical Share Price

 

 

Goldline Pharmaceutical live price: ₹43.06. It opened at ₹43 vs previous close ₹43; intraday high/low: ₹44/₹43.

Goldline Pharmaceutical Performance

  • Today's Low
  • ₹43
  • Today's High
  • ₹44
  • 52 Week Low
  • ₹41
  • 52 Week High
  • ₹60
  • Open Price₹43
  • Previous Close₹43
  • Volume15,000
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Goldline Pharmaceutical Chart

Investment Returns

  • Over 1 Month -6.68%

Smart Investing Starts Here Start SIP with Goldline Pharmaceutical for Steady Growth!

Invest Now

Goldline Pharmaceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 10
  • PEG Ratio
  • -
  • Market Cap Cr
  • 41
  • P/B Ratio
  • 3.1
  • Average True Range
  • 2.79
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 36.45
  • MFI
  • 36.2

Goldline Pharmaceutical Financials

Goldline Pharmaceutical Technicals

EMA & SMA

Current Price
₹43.06
-0.19 (-0.44%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 0
  • 20 Day
  • ₹45.20
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

43.19 Pivot Speed
  • R3 43.87
  • R2 43.69
  • R1 43.37
  • S1 42.87
  • S2 42.69
  • S3 42.37

Goldline Pharmaceutical Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-09 Audited Results

Goldline Pharmaceutical Shareholding Pattern

57.29%
5.16%
0.09%
25.14%
12.32%

Goldline Pharmaceutical FAQs

Goldline Pharmaceutical share price is ₹43 As on 30 June, 2026 | 05:32

The Market Cap of Goldline Pharmaceutical is ₹41.3 Cr As on 30 June, 2026 | 05:32

The P/E ratio of Goldline Pharmaceutical is 10 As on 30 June, 2026 | 05:32

The PB ratio of Goldline Pharmaceutical is 3.1 As on 30 June, 2026 | 05:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23